Molecular science

Retatrutide Explained: One Peptide, Three Receptors

Retatrutide is one synthetic peptide that can activate three different receptors on cells. Its activity depends on the contacts it makes: change the peptide or the receptor, and the signal can change. Follow that connection from the molecule’s components to the cell experiments that test what they do.

One molecule, three possible receptor targets. Each branch represents a separate interaction; activity must be measured at each receptor.

By Freedom Peptides · 2026-09-20 · 6 min read

Three receptor targets: what “triple agonist” means

A receptor is a protein that receives a molecular signal. An agonist binds to a receptor and promotes its activation. Calling retatrutide a triple agonist identifies the three targets it can activate; it does not say that its activity is equal at each one. [5] [7]

Those targets are the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). Each is named for a naturally occurring peptide signal. These are proteins on the cell, not three ingredients mixed into retatrutide. [2]

The distinction matters when you read a study: a result at the glucagon receptor answers a question about that receptor. To understand the full three-target profile, researchers need measurements at each target.

Follow the signal: from the cell surface to the cell interior

Retatrutide’s targets are class B1 G protein-coupled receptors (GPCRs). They span the cell membrane, connecting an outer-facing binding site to signaling machinery inside. A peptide can start a signal there without first entering the cell. [2] [5]

The sequence below follows a shared signaling pathway. What happens afterward depends on the cell and the proteins it contains. A cell must carry a relevant receptor to respond through that target. [5] [6]

Step	What happens
1. Make contact	The peptide associates with the receptor’s binding site. This is binding; activation is the next part of the process. [7]
2. Relay the signal	An activated receptor can engage the stimulatory G protein, called Gs, on the inside of the membrane. [7]
3. Make a messenger	Gs stimulates adenylyl cyclase. This enzyme converts adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP), a small molecule that carries the signal inside the cell. [6]
4. Change protein activity	One route onward is protein kinase A (PKA). This enzyme adds phosphate groups to other proteins, which can change their activity. The response depends on which proteins are present. [6]

1. Make contact

What happens: The peptide associates with the receptor’s binding site. This is binding; activation is the next part of the process. [7]

2. Relay the signal

What happens: An activated receptor can engage the stimulatory G protein, called Gs, on the inside of the membrane. [7]

3. Make a messenger

What happens: Gs stimulates adenylyl cyclase. This enzyme converts adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP), a small molecule that carries the signal inside the cell. [6]

4. Change protein activity

What happens: One route onward is protein kinase A (PKA). This enzyme adds phosphate groups to other proteins, which can change their activity. The response depends on which proteins are present. [6]

Retatrutide engages a cell-surface receptor, which signals through a stimulatory G protein and adenylyl cyclase to produce the intracellular messenger cyclic adenosine monophosphate. — Follow one receptor interaction through the first signaling steps. This conceptual diagram does not show every downstream pathway or the proteins’ exact shapes and locations.

What retatrutide is made of—and why the details matter

Retatrutide, also called LY3437943, has a backbone of 39 amino-acid building blocks joined by peptide bonds. A building block within a chain is called a residue. Their order is the sequence; their side chains are chemical groups that influence shape and molecular contacts. [1] [3]

The chain also contains selected modifications. Read the numbered positions from the amino end, called the N-terminus, toward the opposite end, called the C-terminus. The table connects each feature to the question it helps explain. [3]

Component	Why it matters
The 39-residue backbone	The order and chemistry of these building blocks help determine how the peptide fits a receptor. Having the same chain length would not make another peptide equivalent. [1] [3]
Modified residue at position 2	2-aminoisobutyric acid (Aib) helps resist cleavage by dipeptidyl peptidase-4 (DPP-4), an enzyme that clips the beginning of certain peptides. This does not prevent every form of degradation. [4]
Modified residues at 13 and 20	Position 13 contains alpha-methyl-L-leucine; position 20 contains another Aib. The cell comparison below tests what happens when both are replaced. [4]
Linker and lipid at lysine 17	A chemical bridge connects this residue to a 20-carbon fatty diacid. Attaching a lipid, called lipidation, can promote binding to albumin, a separate carrier protein, and influence receptor activity. [1] [4]
An amide at the final serine	The chain ends in –CONH₂, an amide group, instead of the free acid group –COOH. This is an end modification, not an extra backbone residue. [1]

The 39-residue backbone

Why it matters: The order and chemistry of these building blocks help determine how the peptide fits a receptor. Having the same chain length would not make another peptide equivalent. [1] [3]

Modified residue at position 2

Why it matters: 2-aminoisobutyric acid (Aib) helps resist cleavage by dipeptidyl peptidase-4 (DPP-4), an enzyme that clips the beginning of certain peptides. This does not prevent every form of degradation. [4]

Modified residues at 13 and 20

Why it matters: Position 13 contains alpha-methyl-L-leucine; position 20 contains another Aib. The cell comparison below tests what happens when both are replaced. [4]

Linker and lipid at lysine 17

Why it matters: A chemical bridge connects this residue to a 20-carbon fatty diacid. Attaching a lipid, called lipidation, can promote binding to albumin, a separate carrier protein, and influence receptor activity. [1] [4]

An amide at the final serine

Why it matters: The chain ends in –CONH₂, an amide group, instead of the free acid group –COOH. This is an end modification, not an extra backbone residue. [1]

Retatrutide’s 39-residue backbone highlights modified positions 2, 13 and 20, a linker and lipid attachment at lysine 17, and the terminal amide. — Use the numbered positions to locate the features in the table. Each dot represents one backbone residue; spacing is schematic.

Two cell studies that connect structure to activity

A proposed molecular contact becomes more convincing when changing it changes a measured response. The two studies below approach that question from opposite sides: alter the receptor, or alter the peptide.

Li and colleagues’ 2024 study used cryogenic electron microscopy (cryo-EM) to examine retatrutide bound to each receptor and Gs. The peptide formed a helix, with its amino end reaching into the receptor pocket. The team then tested receptor changes in cells. [2]

Both studies used engineered cell lines for signaling measurements. These are in vitro experiments—work outside a living organism—designed to make particular interactions measurable. [2] [4]

What changed?	What researchers observed	What you can learn
A contact in the glucagon receptor	Li and colleagues report about eightfold lower cAMP signaling potency after one receptor alteration. [2]	A contact in the receptor contributes to the response. “Lower potency” means a higher concentration was needed; the next section explains why that distinction matters.
Two positions in the peptide	Dinsmore and colleagues replaced the modified residues at 13 and 20 with leucine and glutamine. This variant had markedly lower potency at all three receptors in a signaling-responsive reporter assay. [4]	The modified residues matter to activity in this model. Because both changed together, this comparison cannot tell us what each position contributes by itself.

A contact in the glucagon receptor

What researchers observed: Li and colleagues report about eightfold lower cAMP signaling potency after one receptor alteration. [2]
What you can learn: A contact in the receptor contributes to the response. “Lower potency” means a higher concentration was needed; the next section explains why that distinction matters.

Two positions in the peptide

What researchers observed: Dinsmore and colleagues replaced the modified residues at 13 and 20 with leucine and glutamine. This variant had markedly lower potency at all three receptors in a signaling-responsive reporter assay. [4]
What you can learn: The modified residues matter to activity in this model. Because both changed together, this comparison cannot tell us what each position contributes by itself.

Does “less potent” mean a smaller maximum response?

It need not. Potency describes the concentration needed to produce a response. Maximum response describes how far the measured signal rises. Two curves can reach a similar upper level even when one requires a higher concentration to get there. [8]

Look for the half-maximal effective concentration (EC50): the concentration halfway between the bottom and top of a compound’s response curve. A lower EC50 means greater potency in that assay. It does not automatically mean a larger maximum response. [8]

That is how to read the receptor-change example above: the experiment concerns the concentration needed for signaling. Before concluding that the cell has lost its ability to respond, examine the top of the curve as well as its midpoint.

Binding strength is another question. Affinity describes binding; potency describes a response. Receptor abundance and signal amplification can change the relationship between them. This is why a cAMP result alone cannot establish how tightly a peptide binds, or predict an identical response in another cell system. [7]

Put it to use: read one retatrutide experiment

Open Figure 1e and Supplementary Table S5 in Li and colleagues’ paper. Choose one receptor alteration and compare it with the unchanged receptor. The figure shows concentration–response curves; the table reports fitted potency and maximum-response values. [2]

Use these three questions to turn the figure into a specific statement about the experiment.

Ask this	What to look for
What was changed?	Locate the receptor alteration being tested. Keep a receptor change separate from a change to retatrutide’s own sequence.
What moved on the curve?	Compare the concentration needed for a response and the upper response level. Describe these separately.
How far does the finding reach?	Keep the receptor, cell model and measured signal attached to the result. It is evidence about that experiment, not every cell or biological outcome.

What was changed?

What to look for: Locate the receptor alteration being tested. Keep a receptor change separate from a change to retatrutide’s own sequence.

What moved on the curve?

What to look for: Compare the concentration needed for a response and the upper response level. Describe these separately.

How far does the finding reach?

What to look for: Keep the receptor, cell model and measured signal attached to the result. It is evidence about that experiment, not every cell or biological outcome.

Find more in vitro papers and evaluate their evidence →

Explore the molecular structure

To examine the shape behind the signaling, open entry 8YW3 in the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB). It contains the retatrutide–GLP-1R–Gs complex. This is a structural model derived from microscopy data; it is not a movie of an intact cell. [9]

The studies discussed here explain molecular recognition and laboratory signaling. They do not establish effects in people or verify the identity, composition or suitability of a particular Freedom Peptides batch.

Compare all three: semaglutide, tirzepatide and retatrutide →

References

For laboratory research education only. Not for human consumption, dosing or treatment guidance.

← Back to Research Library